Sodium phenyl butyrate downregulates endothelin-1 expression in cultured human endothelial cells: Relevance to sickle-cell disease

Odievre, MH; Brun, M; Krishnamoorthy, R; Lapoumeroulie, C; Elion, J

HERO ID

1458284

Reference Type

Journal Article

Year

2007

Language

English

PMID

17373676

HERO ID 1458284
In Press No
Year 2007
Title Sodium phenyl butyrate downregulates endothelin-1 expression in cultured human endothelial cells: Relevance to sickle-cell disease
Authors Odievre, MH; Brun, M; Krishnamoorthy, R; Lapoumeroulie, C; Elion, J
Journal American Journal of Hematology
Volume 82
Issue 5
Page Numbers 357-362
Abstract As hydroxyurea (HU), sodium phenyl butyrate (SPB) is known to induce fetal hemoglobin (HbF) expression and thus shows potentials for sickle-cell disease (SCD) treatment. More recently, few studies suggested that endothelial cells (ECs), a major pathophysiological actor of SCD, are also a target of SPB. Here, we show that SPB, as HU, reduces endothelin-1 mRNA expression and peptide release by human ECs in culture. SPB increases VCAM-1 and ICAM-1 mRNAs and soluble ICAM-1 release. Both drugs have a cumulative effect on ICAM-1 expression. We conclude that SPB, as HU, also affects the expression of molecules important to the pathophysiology of SCD, in addition to its effect on HbF. Its potential as an alternative or adjuvant drug in SCD treatment warrants further investigations.
Doi 10.1002/ajh.20709
Pmid 17373676
Wosid WOS:000245871300004
Is Certified Translation No
Dupe Override No
Comments Source: Web of Science WOS:000245871300004
Is Public Yes
Language Text English
Keyword sodium phenyl butyrate; endothelium; endothelin-1; sickle-cell disease